Data updated: Mar 29, 2026
OLINVYK
OLICERIDINE
Approved 2020-08-07
1
Indication
--
Phase 3 Trials
5
Years on Market
Details
- Status
- Discontinued
- First Approved
- 2020-08-07
- Routes
- INTRAVENOUS
- Dosage Forms
- SOLUTION
OLINVYK Approval History
Loading approval history...
What OLINVYK Treats
1 FDA approvalsOriginally approved for its first indication in 2020 .
- Other (1)
🔬
Pro Active Pipeline
Ongoing clinical trials by development phase
Loading...
⭐
Pro Key Completed Trials
Completed studies with published results, ranked by significance
Loading...
📊
Trial Timeline
Full development history with FDA approval milestones
|
Loading...
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
OLINVYK FDA Label Details
ProOLINVYK Patents & Exclusivity
Latest Patent: Mar 2032
Patents (45 active)
US11931350
Expires Mar 23, 2032
US9642842
Expires Mar 23, 2032
US8835488
Expires Mar 23, 2032
US9309234
Expires Mar 23, 2032
US11077098
Expires Mar 23, 2032
+ 35 more patents
Source: FDA Orange Book
Want competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.